December 2022, Vol 3, No 4

Milind Javle, MD, of the MD Anderson Cancer Center, led off the roundtable dialogue on emerging therapies in biliary tract cancers (BTCs) with a discussion around methylthioadenosine phosphorylase (MTAP) loss in cholangiocarcinoma (CCA). MTAP is located on the 9p21 chromosome, where CDKN2A/B is also located.

Mark Schattner, MD, FASGE, AGAF, of Memorial Sloan Kettering Cancer Center, discussed endoscopic biliary drainage (EBD) in cholangiocarcinoma (CCA), specifically in hilar obstruction, emphasizing the different goals and techniques in patients with resectable versus unresectable disease. The ultimate goals for management of obstruction in patients with resectable CCA are to optimize them for surgery and avoid perioperative complications and unnecessary procedures.